Publications by authors named "Sanam Razeghi"
Overcoming imposter syndrome, addressing microaggressions, and defining professional boundaries.
Lancet Gastroenterol Hepatol
November 2021
Cannabis use is common in the setting of inflammatory bowel disease (IBD). Patients frequently use cannabis to treat IBD-associated symptoms, and there is evidence that cannabis and its derivatives are helpful for this purpose. However, it is unclear how the symptom profiles of active IBD cannabis users and nonusers compare and how these symptoms may relate to their underlying disease state and/or complications.
View Article and Find Full Text PDFHepatitis D virus (HDV) infection may accompany acute or chronic hepatitis B virus infection. While HDV infection in the United States is thought to be uncommon, there are limited data regarding frequency of testing, and prevalence of HDV antibody and HDV RNA. We evaluated the use of HDV antibody testing using electronic medical record (EMR) data.
View Article and Find Full Text PDFA 58-year-old man with end-stage renal disease presented with hypotension and emesis, pale conjunctivae, and a distended abdomen. Labs revealed hypercalcemia and leukocytosis. Abdominal imaging showed gastric pneumatosis.
View Article and Find Full Text PDFArticle Synopsis
- Occult hepatitis B virus (HBV) is identified by detecting HBV DNA without the presence of HBsAg in patients, which can lead to serious health risks like liver cancer and transmission to others.
- A case of a 21-year-old woman with severe endocarditis attributed to intravenous drug use revealed elevated liver enzymes and the presence of occult HBV, despite her receiving the hepatitis B vaccine.
- The findings suggest that while infant vaccination is effective against chronic HBV, it may not prevent occult HBV, highlighting the need for thorough HBV testing in high-risk individuals, regardless of vaccination history or detectable antibodies.
Background: Recent studies have demonstrated superior outcomes of early biologic therapy. Our purpose was to evaluate differences in disease course among patients in clinical practice treated with early biologic therapy compared with those receiving conventional Step Up therapy.
Methods: Patients with Crohn's disease evaluated from July 2004 to November 2010 at a tertiary referral center were included.